Weak science behind AI health hype | PitchBook News Summary

1. Key Themes

Theme 1: AI + Consumer Health = Funding Surge With a Scientific Credibility Gap

$500 million in VC poured into gut health startups last year alone, but founders are running ahead of the science. The article surfaces real tension between investor enthusiasm and clinical legitimacy.

"Last year alone saw $500 million in venture capital invested in gut health startups, but there's still a lot the scientific community doesn't know."

"There are companies that will give you tailored data and say, 'You should purchase this probiotic from us.' To that, I would preach a lot of caution." — Max Brondfield, UCSF

Theme 2: Europe's AI VC Boom Is Real but Geographically and Sectorally Uneven

AI now accounts for nearly 1 in 4 VC-backed European startups and 62% of all deal value so far in 2026 — but growth is concentrated in early-stage companies and legacy software verticals, leaving fintech, cleantech, and wellness comparatively underserved.

"AI funding making up 62% of all VC deal value so far this year—but a handful of regions and sectors are doing most of the heavy lifting."

"AI activity remains heavily concentrated in traditional software verticals such as SaaS and big data, with comparatively limited adoption in fintech, cleantech and wellness—sectors where the next wave of growth is likely to emerge."

Theme 3: OpenAI Democratizes Private Equity Access Pre-IPO via ETFs

OpenAI's $122 billion round at an $852 billion valuation opens a historic new channel — ETF vehicles led by Cathie Wood — allowing retail investors to access a pre-IPO AI giant for the first time.

"Before its IPO, OpenAI is already selling to the public through Cathie Wood-led ETFs."

"OpenAI raised a $122 billion round led by investors including SoftBank, Andreessen Horowitz and DE Shaw Ventures at an $852 billion valuation."

Theme 4: Mega-Deals Are Dominating M&A Activity

McCormick's $44.8B acquisition of Unilever's food business is emblematic of a structural shift where large transactions are crowding out mid-market activity.

"McCormick agreeing to acquire Unilever's food business for $44.8 billion, adding to a surge in mega-deals—which accounted for 56.6% of global M&A value last year."

Theme 5: The Secondary Market Is Exploding in Value

Direct secondary market value nearly doubled from 2024 to 2025, signaling a structural shift in how liquidity is being manufactured in the private markets.

"Secondaries are increasingly gaining traction, and as a result, direct secondary market value has nearly doubled from 2024 to 2025." — PitchBook Chart of the Day

2. Contrarian Perspectives

The AI Health Advice Boom May Be Selling False Precision

The prevailing narrative is that AI + personal health data = better outcomes. The article challenges this by highlighting the microbiome's fundamental complexity — patients who follow AI-powered probiotic recommendations frequently report no benefit, and the science simply doesn't yet support the personalization being marketed.

"Viome has come under scrutiny for marketing customized supplements to users after they receive the results of its testing kit."

"[Patients will] say, 'I tried the recommended probiotic, and it didn't do anything.'" — Max Brondfield, UCSF

"There are still so many interactions in the microbiome that we don't understand." — Max Brondfield, UCSF

Opening 401(k)s to Alternatives Will Hurt, Not Help, the Secondary Market

Conventional wisdom suggests that more retail access to private assets is a tailwind for the whole ecosystem. But PitchBook's analysis suggests the proposed 401(k) rule change actually disadvantages secondary market players — a non-obvious second-order effect.

"The secondary market stands as a clear loser in the government's proposed rule to open 401(k)s to alternative assets."

Evergreen Funds Are More Expensive Than They Appear

Evergreen funds are being marketed to wealth channels as accessible, low-friction alternatives vehicles. However, disclosed fees in prospectuses materially understate total cost to LPs.

"Evergreen funds may cost more than you think. Prospectuses don't disclose the full extent of performance fees that LPs are on the hook for, according to a Morningstar analysis."

3. Companies Identified

OpenAI

Description: Leading AI lab and developer of ChatGPT
Why Mentioned: Raised a record $122B round at an $852B valuation; making history by allowing pre-IPO access through Cathie Wood ETFs; also noted for launching AI wellness advice systems
Quote: "OpenAI raised a $122 billion round led by investors including SoftBank, Andreessen Horowitz and DE Shaw Ventures at an $852 billion valuation."

Viome

Description: Khosla Ventures-backed gut health startup offering microbiome testing and personalized supplement recommendations
Why Mentioned: Case study in the AI health credibility problem; under scrutiny for marketing supplements based on test results that lack scientific validation
Quote: "Viome, for example, says that it can offer more personalized recommendations than a dietician. But there are still so many interactions in the microbiome that we don't understand."

Throne

Description: Hardware startup selling a toilet-attachable device that analyzes bowel and urinary health
Why Mentioned: Illustrative example of startups building AI health coaching features on top of physiological data streams
Quote: "We're actively building that feature right now, we call it the gut health coach." — Scott Hickle, Founder

Ritual

Description: Consumer supplements brand backed by Norwest Venture Partners
Why Mentioned: Cited as an example of a trust-forward approach to the wellness category, favored by investors as a model for building credibility with skeptical consumers
Quote: "As investors, one of the things we think about is what are the things you can do to build trust among the skeptics." — Lisa Wu, Norwest

Saronic

Description: Developer of autonomous ships and maritime defense technology
Why Mentioned: Raised a $1.75B Series D led by Kleiner Perkins at a $9.25B valuation — a standout defense-tech deal
Quote: "Saronic, which develops autonomous ships and other maritime defense tech, secured a $1.75 billion Series D led by Kleiner Perkins at a $9.25 billion valuation."

Whoop

Description: Wearable fitness band company
Why Mentioned: Raised a $575M Series G at a $10.1B valuation led by Collaborative Fund, signaling continued investor appetite for consumer health hardware
Quote: "Wearable fitness band specialist Whoop raised a $575 million Series G led by Collaborative Fund at a $10.1 billion valuation."

Fractile

Description: London-based AI chip developer
Why Mentioned: In talks to raise $200M+ at a $1B valuation; notable as a European AI infrastructure play
Quote: "London-based AI chip developer Fractile is in talks to raise more than $200 million at a $1 billion valuation."

Sycamore

Description: Autonomous enterprise AI platform
Why Mentioned: Raised a $65M seed round — notable for its size at seed stage — led by Coatue and Lightspeed
Quote: "Sycamore, which offers an autonomous enterprise AI platform, received a $65 million seed round led by Coatue and Lightspeed."

Depthfirst

Description: AI lab developing a threat and vulnerability detection model (cybersecurity)
Why Mentioned: Raised an $80M Series B led by Meritech Capital; represents AI's expansion into cybersecurity
Quote: "Depthfirst, an AI lab developing a threat and vulnerability detection model, raised an $80 million Series B led by Meritech Capital."

Eli Lilly / Centessa Pharmaceuticals

Description: Eli Lilly acquiring sleep disorder treatment developer Centessa
Why Mentioned: $7.8B deal signals continued large pharma appetite for clinical-stage biotech in specialized therapeutic areas
Quote: "Eli Lilly agreed to acquire Centessa Pharmaceuticals, which develops treatments for sleep disorders, in a $7.8 billion deal."

Standing Ovation

Description: Paris-based precision fermentation startup
Why Mentioned: Secured a €25M Series B; represents the emerging European alternative protein/food tech sector
Quote: "Standing Ovation, a Paris-based precision fermentation startup, secured a €25 million Series B led by Bpifrance and Credit Mutuel Innovation."

4. People Identified

Max Brondfield

Description: Assistant Professor, Division of Gastroenterology, University of California, San Francisco
Why Mentioned: Primary scientific skeptic in the gut health AI story; provides the clinical grounding that challenges startup claims
Quote: "There are companies that will give you tailored data and say, 'You should purchase this probiotic from us.' To that, I would preach a lot of caution."

Scott Hickle

Description: Founder of Throne, a toilet-attachable health analytics device
Why Mentioned: Represents the founder perspective building AI health features atop novel biometric data
Quote: "We're actively building that feature right now, we call it the gut health coach."

Caroline Lippman

Description: Investor in consumer health startups at Coefficient Capital
Why Mentioned: Provides investor framing on the social media-driven gut health trend and its intersection with consumer behavior
Quote: "On TikTok, there's a huge swath of influencers and everyday people talking about this new supplement they tried."

Lisa Wu

Description: Partner at Norwest Venture Partners; invested in Ritual
Why Mentioned: Offers an investor framework for navigating the gut health credibility challenge — prioritizing trust-building with skeptics — while remaining bullish on the category
Quote: "We love fiber. We think there are new opportunities to make fiber sexy."

Douglas Leone

Description: Veteran investor at Sequoia Capital
Why Mentioned: Named as Sequoia's new Chairman
Quote: "Sequoia named Douglas Leone as chairman."

5. Operating Insights

Build Trust Before You Build Claims — Especially in Health

The gut health market is being destabilized by overreaching scientific claims. Investors explicitly name trust-building with skeptics as a key differentiator. Founders who position conservatively and let data accumulate over time may win durable brand equity while aggressive claimants face regulatory and reputational risk.

"As investors, one of the things we think about is what are the things you can do to build trust among the skeptics." — Lisa Wu, Norwest

Smaller European Ecosystems Are Punching Above Their Weight in AI Concentration

For founders seeking less competition for deals and talent, and for investors looking for alpha outside saturated hubs, Portugal and the Czech Republic offer disproportionate AI ecosystem density relative to market size — and may offer better entry valuations than the UK, France, or Germany.

"Countries such as Portugal and the Czech Republic have a much higher proportion of their startup ecosystems concentrated around AI than bigger markets. Smaller hubs tend to be more specialized in a few strategic sectors, such as AI."

6. Overlooked Insights

The US AI VC Market May Be Too Crowded — Making Europe Relatively More Attractive

While the European AI story is framed as a growth narrative, buried in the data is a signal that the US market may be approaching saturation — with nearly 90% of all US VC going to AI. This could structurally redirect LP and founder capital toward Europe where dry powder competition is lower and non-AI sectors remain more accessible.

"In the US, the market is even more saturated, with almost 90% of total VC investment going to AI, which could make Europe more attractive for deals."

AI's Penetration of European Fintech, Cleantech, and Wellness Remains Low — a Potential Whitespace

Despite record AI funding in Europe, three of the highest-value sectors have seen relatively little AI adoption. This represents a concrete, data-backed gap for founders and investors to target before the wave arrives.

"AI activity remains heavily concentrated in traditional software verticals such as SaaS and big data, with comparatively limited adoption in fintech, cleantech and wellness—sectors where the next wave of growth is likely to emerge."